Tagged with R

Hong Kong Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative drug development in China, and the challenges of establishing a biotech company in Hong Kong.   Our research within AI…

Coronavirus During the 30 April IFPMA virtual media briefing on COVID-19 treatments, key global executives pushed beyond catchy headlines to discuss the current reality of COVID-19 R&D efforts.   MSD (Merck & Co. in the US and Canada) executive vice president and chief patient officer Julie Gerberding drew upon her valuable…

India COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and active pharmaceutical ingredients for the last month. With restrictions beginning to ease up, some manufacturing hubs are back in operation.    After over a month of lockdown and significantly reduced manufacturing capacity, the international pharma…

USA Dr Gerard Anderson of Johns Hopkins University Bloomberg School of Public Health critiques the US response to the COVID-19 pandemic, before explaining how access and affordability in the US can be improved, and his outlook on the future of American public health.   To some extent, we are the poster…

Morocco Morocco has made admirable progress in building a national oncology network in recent years, but the country’s cancer patients still face significant challenges in terms of accessing the latest therapies. Here, the Morocco heads of companies with global portfolios of innovative cancer treatments discuss the current situation and how they…

Morocco Taher Hassen has been in position as GM for Morocco and Tunisia at Merck for four years, overseeing year-on-year double-digit growth for the affiliate ever since. His current priorities include facilitating greater access to innovation within Morocco and bringing Merck’s world-class technological know-how to the country.   Merck has been…

Morocco Iberma, one of the leading domestic pharma manufacturers in Morocco, has evolved significantly since its founding in 1994 to become the market leader in several therapeutic areas. The company also has an increasingly international footprint, with plans to capture new opportunities in Africa and Europe.   Karim Lahlou, who took…

Opinion Brendan Shaw takes a look at the rise of drone technology in medical product delivery and its implications for the future of healthcare.   What was once thought of as science fiction even a few years ago is rapidly becoming a commercial reality. While we have not yet seen regular…

Coronavirus In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He explained the firm’s collaboration with US research group BARDA and underscored that Sanofi is committed to bringing vaccines to all…

Coronavirus In an interview with Financial Times correspondent Leila Abboud at the FT Global Boardroom video conference on the 14th of May, Paul Hudson, CEO of French pharma firm Sanofi underscored the joint efforts between his company and GSK in hopes of bringing a viable Covid-19 vaccine to market more quickly.…

China Dr Joan Shen, CEO of I-Mab Biopharma, shares her impressive career journey across companies like Pfizer, Janssen and Jiangsu Hengrui, before joining I-Mab, as well as introducing what I-Mab 2.0 might look like for the NASDAQ-listed biotech, their clinical pipeline and her leadership philosophy.   Fundamentally, we need to keep…

Hong Kong Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy to develop their brand in South East Asia, the changes he foresees for the industry post the COVID-19 pandemic, and…